Related Experiment Videos
Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients
A Haenni1, M Ohrvall, H Lithell
1Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
Abstract:
Serum magnesium concentration (S-Mg) has been reported to be inversely associated with atherogenic lipid fractions and with blood glucose concentrations. In some studies on humans, oral magnesium supplementation has been found to improve the lipoprotein balance. Against this background the present study was undertaken to determine whether reductions in atherogenic lipid fractions are associated with S-Mg alterations. Total S-Mg was measured in 23 patients with non-insulin-dependent diabetes mellitus (NIDDM) treated with the lipid-lowering drugs gemfibrozil and simvastatin in a double-blind cross-over study. The mean S-Mg at the end of the initial placebo period, ie, before active treatment, was 0.80 (SD 0.06) mmol/L. Treatment with gemfibrozil 600 mg twice daily for 4 months decreased S-Mg by 0.02 mmol/L (P =.02), and treatment with simvastatin 10 mg daily for 4 months again decreased S-Mg by 0.02 mmol/L (P =.10; not significant [NS]) The changes in S-Mg during the 2 different treatment periods were closely correlated (r = 0.66, P <.001). Fasting plasma glucose concentrations increased significantly by 17% during both drug regimens. The changes in fasting plasma glucose and S-Mg were significantly correlated both during gemfibrozil treatment (r = -0.56, P <.01) and during treatment with simvastatin (r = -0.44, P <.05). Changes in glucose tolerance or insulin sensitivity did not correlate to changes in S-Mg. The associations between changes in serum very-low-density lipoprotein (VLDL) fractions and S-Mg did not reach statistical significance (r = -0.37, P <.10). Changes in low-density lipoprotein (LDL) cholesterol and S-Mg did not correlate. In conclusion, total S-Mg concentration decreased during treatment with gemfibrozil and simvastatin in patients with NIDDM. During both drug regimens changes in S-Mg status were inversely correlated to changes in plasma glucose concentrations, while changes in lipid status were not significantly correlated with changes in S-Mg.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Dipeptidyl Peptidase 4 Inhibitors
Atherosclerosis III: Management
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...